Drug Development

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

BioCryst is closing its discovery labs to save millions, betting on external partnerships for its next big drug. But what is the hidden cost of this pivot?

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

A breakthrough oral vaccine from Singaporean scientists promises to end a devastating fish virus, bolstering food security and transforming aquaculture economics.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

As pharma giants battle with blockbuster drugs, one company is betting on a simple, non-systemic hydrogel. Is this the future of weight management?

Nomic Bio and the HESI OASIS Consortium partner to map liver toxicity using proteomics, fueling AI models to make drug development safer and more ethical.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?